Bristol-Myers Squibb Company (BMY)

55.47
0.40 0.73
NYSE : Health Care
Prev Close 55.07
Open 55.29
Day Low/High 55.18 / 55.72
52 Wk Low/High 46.01 / 76.80
Volume 3.71M
Avg Volume 7.81M
Exchange NYSE
Shares Outstanding 1.65B
Market Cap 90.18B
EPS 2.70
P/E Ratio 19.01
Div & Yield 1.56 (2.80%)

Latest News

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday

FDA advisory committee poised to make recommendation regarding CAR T therapy from Novartis that represents the first possibility of treatment calling on the body's own engineered cells to attack cancer.

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

My three top predictions for the next six months.

Biotech Movers: Exelixis, Omeros, Inovio

Biotech Movers: Exelixis, Omeros, Inovio

Exelixis, Omeros and Inovio Pharmaceuticals were among the biotech movers in premarket trading on July 10.

Summer Watch List: How Some Key Names Are Stacking Up

Here's what to focus on from these stocks in July.

Exelixis And Bristol-Myers Squibb Initiate Phase 3 Trial Of Opdivo® In Combination With CABOMETYX™ Or Opdivo And Yervoy® In Combination With CABOMETYX, Versus Sunitinib In Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Exelixis And Bristol-Myers Squibb Initiate Phase 3 Trial Of Opdivo® In Combination With CABOMETYX™ Or Opdivo And Yervoy® In Combination With CABOMETYX, Versus Sunitinib In Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the initiation of the phase 3 CheckMate 9ER trial to evaluate Opdivo ® (nivolumab) in combination with CABOMETYX™...

What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers

What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers

The FDA has placed a clinical hold on three combination studies of Merck's Keytruda in multiple myeloma.

Bristol Myers Vies to Be King of Immune-Boosting Cancer Drugs with New Trial Update

Bristol Myers Vies to Be King of Immune-Boosting Cancer Drugs with New Trial Update

The trial's success props open doors for exploring new uses for Opdivo's treatment in immunotherapy.

Celgene Enters PD1 Market with BeiGene Deal

Celgene Enters PD1 Market with BeiGene Deal

Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.

Bristol-Myers Squibb's ORENCIA (abatacept) Receives FDA Approval For Treatment Of Active Psoriatic Arthritis (PsA) In Adults

Bristol-Myers Squibb's ORENCIA (abatacept) Receives FDA Approval For Treatment Of Active Psoriatic Arthritis (PsA) In Adults

Bristol-Myers Squibb Company (NYSE:BMY) announced today the U.

Keep Your Eyes on the Bonds

Is this just a retest or a new leg down?

Intermediate Trade: Bristol-Myers Squibb

Intermediate Trade: Bristol-Myers Squibb

The trade is the out-of-the-money, bullishly biased vertical call spread expiring in August.

Phase 3 Study Evaluating the Safety And Efficacy Of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint

Phase 3 Study Evaluating the Safety And Efficacy Of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint

Bristol-Myers Squibb Company (NYSE:BMY) announced today that a Phase 3 study evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma who are at high risk of...

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

Ready. Raise. Rise. Spokespeople Tia Mowry, Eric Stonestreet And Dak Prescott (Photo: Business Wire)

Eric Stonestreet of television's hit comedy "Modern Family" and new reality competition series, "The Toy Box," is once again lending his star power to the Ready.

Four-Year Follow-up With Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) In Patients With Advanced Multiple Myeloma Shows Long-term Efficacy In ELOQUENT-2 Trial

Bristol-Myers Squibb Company (NYSE:BMY) presented four-year follow-up data from the Phase 3 ELOQUENT-2 study in which Empliciti (elotuzumab) plus lenalidomide/dexamethasone (ELd) continued to demonstrate efficacy in...

Cramer: Stop Talking About the 'Market'

Cramer: Stop Talking About the 'Market'

It just isn't as useful or descriptive right now.

Major Talc Case Against J&J Declared a Mistrial Following SCOTUS Ruling

Major Talc Case Against J&J Declared a Mistrial Following SCOTUS Ruling

The court ruled that state courts can't hear claims against an out-of-state company if the alleged injuries didn't occur there.

Bristol-Myers Squibb Announces The Expiration Of Its Cash Tender Offer

Bristol-Myers Squibb Company (NYSE:BMY) announced today the expiration, as of 5:00 p.

Bristol-Myers Squibb Announces The Pricing Terms Of Its Cash Tender Offer For Any And All Of Certain Of Its Outstanding Debt Securities

Bristol-Myers Squibb Company (NYSE:BMY) announced today the pricing terms of its previously announced cash tender offer for any and all of certain of its outstanding debt securities.

Bristol-Myers Squibb Is Poised for a Breakout

Bristol-Myers Squibb Is Poised for a Breakout

Shares of BMY finished Monday at new June highs and are now set up well for an upside breakout.

Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales.

On Betting Against the Bonds and Panicking off the Fed: Jim Cramer's Best Blog

On Betting Against the Bonds and Panicking off the Fed: Jim Cramer's Best Blog

Jim Cramer discusses bonds and also talks about why panicking off the Fed is a superbad idea.

Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response In Adult Patients With Relapsed Or Progressed Classical Hodgkin Lymphoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced extended follow-up data in which Opdivo (nivolumab) demonstrated responses in adult patients with relapsed or progressed classical Hodgkin lymphoma (cHL) after...

Cramer: You Can't Bet Against the Bonds

Cramer: You Can't Bet Against the Bonds

A rotation that started as the minor chord of the rotational symphony and is now the major one.

Bristol-Myers Squibb To Sell Manufacturing Facility In Swords, Ireland To SK Biotek Co., Ltd.

Bristol-Myers Squibb Company (NYSE:BMY) and SK Biotek Co.

Still Waiting for the All-Clear on FANG

Resist the urge to buy; their time will come again.